NO992296D0 - FremgangsmÕte for disubstituerte pyridiner - Google Patents
FremgangsmÕte for disubstituerte pyridinerInfo
- Publication number
- NO992296D0 NO992296D0 NO992296A NO992296A NO992296D0 NO 992296 D0 NO992296 D0 NO 992296D0 NO 992296 A NO992296 A NO 992296A NO 992296 A NO992296 A NO 992296A NO 992296 D0 NO992296 D0 NO 992296D0
- Authority
- NO
- Norway
- Prior art keywords
- disubstituted pyridines
- pyridines
- disubstituted
- Prior art date
Links
- 150000003222 pyridines Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3088096P | 1996-11-14 | 1996-11-14 | |
| PCT/IB1997/001367 WO1998021184A1 (en) | 1996-11-14 | 1997-11-03 | Process for substituted pyridines |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO992296L NO992296L (no) | 1999-05-12 |
| NO992296D0 true NO992296D0 (no) | 1999-05-12 |
Family
ID=21856496
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO992296A NO992296D0 (no) | 1996-11-14 | 1999-05-12 | FremgangsmÕte for disubstituerte pyridiner |
Country Status (32)
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999052892A2 (en) * | 1998-04-08 | 1999-10-21 | Novartis Ag | Novel herbicides |
| US6090942A (en) * | 1998-10-15 | 2000-07-18 | Pfizer Inc. | Process and intermediates for a β3 -adrenergic receptor agonist |
| KR20010102198A (ko) * | 1999-02-16 | 2001-11-15 | 후루타 타케시 | 치환 아세틸피리딘 유도체 및 그를 이용하는 광학활성 β3작용제 중간체의 제조 방법 |
| US6455734B1 (en) | 2000-08-09 | 2002-09-24 | Magnesium Diagnostics, Inc. | Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states |
| ES2228413T3 (es) * | 1999-07-23 | 2005-04-16 | Pfizer Products Inc. | Productos intermedios y un procedimiento para producir agonistas de receptores beta-adrenergicos. |
| US20040265991A1 (en) * | 2001-10-17 | 2004-12-30 | Naoaki Taoka | Process for preparation of (s)-alpha-halomethylpyridine-methanol derivatives |
| BR0307996A (pt) | 2002-02-27 | 2004-12-07 | Pfizer Prod Inc | Processos e intermediários úteis na preparação de receptores de agonistas beta3-adrenérgicos |
| US6864268B2 (en) | 2002-02-27 | 2005-03-08 | Pfizer Inc. | β3 adrenergic receptor agonists |
| AU2003209527A1 (en) * | 2002-02-27 | 2003-09-09 | Pfizer Products Inc. | Crystal forms of (r)-2-(2-(4-oxazol-4-yl-phenoxy)-ethylamino)-1-pyridin-3-yl-ethanol |
| EP1424079A1 (en) * | 2002-11-27 | 2004-06-02 | Boehringer Ingelheim International GmbH | Combination of a beta-3-receptor agonist and of a reuptake inhibitor of serotonin and/or norepinephrine |
| ATE406363T1 (de) | 2003-05-09 | 2008-09-15 | Hoffmann La Roche | Methylindole und methylpyrrolopyridine als alpha- 1-adrenerge agonisten |
| GB2431927B (en) | 2005-11-04 | 2010-03-17 | Amira Pharmaceuticals Inc | 5-Lipoxygenase-activating protein (FLAP) inhibitors |
| US7977359B2 (en) | 2005-11-04 | 2011-07-12 | Amira Pharmaceuticals, Inc. | 5-lipdxygenase-activating protein (FLAP) inhibitors |
| US8399666B2 (en) | 2005-11-04 | 2013-03-19 | Panmira Pharmaceuticals, Llc | 5-lipoxygenase-activating protein (FLAP) inhibitors |
| EP2285803A4 (en) | 2008-05-23 | 2011-10-05 | Amira Pharmaceuticals Inc | Inhibitor of 5-Lipoxygenase Activating Protein |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4358455A (en) | 1980-12-23 | 1982-11-09 | Merck & Co., Inc. | Aralkylamindethanol heterocyclic compounds |
| US5019578A (en) | 1987-11-27 | 1991-05-28 | Merck & Co., Inc. | β-adrenergic agonists |
| ATE154935T1 (de) * | 1993-06-14 | 1997-07-15 | Pfizer | Zweite amine als antidiabetische mittel und für die behandlung von fettleibigkeit |
| IL113410A (en) | 1994-04-26 | 1999-11-30 | Merck & Co Inc | Substituted sulfonamides having an asymmetric center and pharmaceutical compositions containing them |
| CA2220538A1 (en) * | 1995-05-10 | 1996-11-14 | Pfizer Inc. | .beta.-adrenergic agonists |
| JPH11504649A (ja) | 1995-05-10 | 1999-04-27 | ファイザー・インコーポレーテッド | β−アドレナリン作働性アゴニスト |
-
1997
- 1997-11-03 KR KR1019990704312A patent/KR20000053314A/ko active IP Right Grant
- 1997-11-03 JP JP52233298A patent/JP3510635B2/ja not_active Expired - Fee Related
- 1997-11-03 DE DE69735433T patent/DE69735433D1/de not_active Expired - Lifetime
- 1997-11-03 YU YU22099A patent/YU22099A/sh unknown
- 1997-11-03 US US09/297,694 patent/US6291489B1/en not_active Expired - Fee Related
- 1997-11-03 EP EP97945047A patent/EP0938476B1/en not_active Expired - Lifetime
- 1997-11-03 TR TR1999/01063T patent/TR199901063T2/xx unknown
- 1997-11-03 WO PCT/IB1997/001367 patent/WO1998021184A1/en active IP Right Grant
- 1997-11-03 AU AU46346/97A patent/AU4634697A/en not_active Abandoned
- 1997-11-03 AT AT97945047T patent/ATE319687T1/de not_active IP Right Cessation
- 1997-11-03 CA CA002270386A patent/CA2270386C/en not_active Expired - Fee Related
- 1997-11-03 BR BR9712951-8A patent/BR9712951A/pt not_active Application Discontinuation
- 1997-11-03 CN CN97199663A patent/CN1237160A/zh active Pending
- 1997-11-03 IL IL12968897A patent/IL129688A0/xx unknown
- 1997-11-03 EA EA199900375A patent/EA199900375A1/ru unknown
- 1997-11-11 PE PE1997001004A patent/PE10299A1/es not_active Application Discontinuation
- 1997-11-11 GT GT199700118A patent/GT199700118A/es unknown
- 1997-11-11 MA MA24864A patent/MA24401A1/fr unknown
- 1997-11-12 PA PA19978441401A patent/PA8441401A1/es unknown
- 1997-11-12 TN TNTNSN97172A patent/TNSN97172A1/fr unknown
- 1997-11-12 UY UY24774A patent/UY24774A1/es unknown
- 1997-11-12 ZA ZA9710186A patent/ZA9710186B/xx unknown
- 1997-11-12 MY MYPI97005396A patent/MY132507A/en unknown
- 1997-11-12 AR ARP970105279A patent/AR010584A1/es not_active Application Discontinuation
- 1997-11-13 ID IDP973662A patent/ID18898A/id unknown
- 1997-11-13 CO CO97066763A patent/CO4930261A1/es unknown
- 1997-11-13 HR HR60/030,880A patent/HRP970612A2/hr not_active Application Discontinuation
- 1997-11-13 AP APAP/P/1997/001147A patent/AP805A/en active
-
1999
- 1999-04-16 IS IS5029A patent/IS5029A/is unknown
- 1999-05-07 OA OA9900096A patent/OA11044A/en unknown
- 1999-05-11 BG BG103393A patent/BG103393A/xx unknown
- 1999-05-12 NO NO992296A patent/NO992296D0/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO990531D0 (no) | Partikkel-siktanordning | |
| DE69627112D1 (de) | Bettvorrichtung | |
| DE69621432D1 (de) | Bettvorrichtung | |
| DE69520558D1 (de) | Halogenierungsverfahren | |
| KR970001365A (ko) | 알킬하이드로겐클로로실란의 제조방법 | |
| NO992296D0 (no) | FremgangsmÕte for disubstituerte pyridiner | |
| NO974169D0 (no) | Fremgangsmåte for tetra-azacykloalkan-fremstilling | |
| DE69703305D1 (de) | System zum herstellen von polsterelementen | |
| DE69708277T2 (de) | Azeotroper destillationsprozess | |
| IT1291359B1 (it) | Procedimento per fabbricare pannelli truciolari | |
| DE69507032D1 (de) | Chlorhydrin-verfahren | |
| DE69629942D1 (de) | Herstellungsverfahren | |
| DE69729051D1 (de) | Bearbeitungsbetriebsmethode | |
| NO20003079D0 (no) | Polymerisasjon-oppstartningsprosess | |
| MA24472A1 (fr) | Procede | |
| ID24830A (id) | Proses untuk pengolahan laktam | |
| MA24470A1 (fr) | Procede | |
| DE69708229T2 (de) | Muster-Herstellungsverfahren | |
| NO20003080D0 (no) | Polymerisasjon-oppstartningsprosess | |
| DE69811000D1 (de) | System zum Herstellen von Bändern | |
| FI974067A0 (fi) | Process foer cellulasbehandling | |
| BR9709960A (pt) | N-(4-piridil)-tioamidas substituídas | |
| FI980701A (fi) | Menetelmä prosessin kestoajan tarkistamiseksi | |
| LV10943A (lv) | N-benziloksikarbonilarginina 4-metilkumaril-7-amida iegusanas metode | |
| ID23162A (id) | Proses untuk mendekomposisi sikloalkilhidroperoksida |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |